The Hillman Cancer Center Animal Facility (AF) is a biomedical research support program, consisting of staff, services, and facilities dedicated to meeting the animal-dependent needs of the research programs of the University of Pittsburgh Cancer Institute (UPCI). The goal ofthe AF is to provide expertise, advice, facilities, personnel, training, and assistance when cancer-related investigations require the use of animal models. Veterinary technical support, animal modeling consultation, and veterinary interpretive pathologic phenotypic support are partial services covered by the AF. The facility occupies 12,228 net sq. ft. in the Hillman Cancer Center Research Pavilion (HCC), and is designed, managed, and dedicated to maintain specific pathogen free (SPF) rodent populations, using barrier and micro-isolator caging systems and techniques. This Shared Facility is an integral component of the University of Pittsburgh's overall Animal Care Program that is overseen by the Institutional Animal Care and Use Committee. This program is registered with the USDA (23-R0016) and maintains a letter of assurance with the Public Health Service ofthe NIH (A3187-01). It is fully accredited by the Association for the Assessment and Accreditation for Laboratory Animal Care International (AAALAC Int.), which was last received in March of 2008.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Yang, Liangchun; Xie, Min; Yang, Minghua et al. (2014) PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun 5:4436
Zhang, Xuan; Bresee, Jamee; Fields, Gregg B et al. (2014) Near-infrared triple-helical peptide with quenched fluorophores for optical imaging of MMP-2 and MMP-9 proteolytic activity in vivo. Bioorg Med Chem Lett 24:3786-90
Oborski, Matthew J; Demirci, Emre; Laymon, Charles M et al. (2014) Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme. Clin Nucl Med 39:e431-2
Gross, Neil D; Bauman, Julie E; Gooding, William E et al. (2014) Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res 20:3289-98
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Peterson, Lanell M; Kurland, Brenda F; Schubert, Erin K et al. (2014) A phase 2 study of 16*-[18F]-fluoro-17*-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol 16:431-40
Sun, Xiaofang; Tang, Daolin (2014) HMGB1-dependent and -independent autophagy. Autophagy 10:1873-6
Pollock, Sheri L; Rush, Elizabeth A; Redner, Robert L (2014) NPM-RAR, not the RAR-NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiation. Leuk Lymphoma 55:1383-7
Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18
Popovtzer, Aron; Normolle, Daniel; Worden, Francis P et al. (2014) Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: translation from preclinical investigations aiming to improve the therapeutic ratio. Transl Oncol 7:479-83

Showing the most recent 10 out of 463 publications